In the past 36 months, CUC has been a consultant or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Cardio Diagnostics, Compass, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/Johnson & Johnson, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mindpax, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka; served on data safety monitoring boards for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva; has received grant support from Janssen and Takeda; has received royalties from UpToDate; and is also a stock option holder of Cardio Diagnostics, LB Pharma and Mindpax. In the past 36 months, all other authors declare no competing interests. We are indebted to the national centers that make up the WHO Program for International Drug Monitoring and contribute reports to VigiBase. The information comes from a variety of sources, and the probability that the suspected adverse effect is drug-related is not the same in all cases. However, the opinions and conclusions of this study are not necessarily those of the various centers nor of WHO, who helped in the editing of this Correspondence. We acknowledge Lorraine Maw at the Mental Health Research Center at Eastern State Hospital, Lexington, KY, USA, who helped to edit this Correspondence. Ms Maw declares no competing interests in the last 36 months.